SinoMab BioScience Акции в свободном обращении
Что обозначает Акции в свободном обращении в SinoMab BioScience?
Акции в свободном обращении SinoMab BioScience Limited является 259.218M 25.76%
Какое определение для Акции в свободном обращении?
Акции в свободном обращении - это часть акций корпорации, которые находятся в руках государственных инвесторов, а не заблокированных акционерных капиталах.
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Акции в свободном обращении компаний в Health Care сектор на HKSE по сравнению с SinoMab BioScience
Что делает SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Компании с акции в свободном обращении похож на SinoMab BioScience
- NXP Semiconductors N.V имеет Акции в свободном обращении из 258.694M 87.54%
- Bortex Global имеет Акции в свободном обращении из 258.720M 51.74%
- Wing Chi имеет Акции в свободном обращении из 258.751M 27.71%
- Luzheng Futures имеет Акции в свободном обращении из 258.811M 93.40%
- Kinnevik AB имеет Акции в свободном обращении из 258.831M 107.08%
- The Lakshmi Vilas Bank имеет Акции в свободном обращении из 258.892M 76.89%
- SinoMab BioScience имеет Акции в свободном обращении из 259.218M 25.76%
- Klondike Silver имеет Акции в свободном обращении из 259.330M 98.92%
- Lucero имеет Акции в свободном обращении из 259.334M 39.15%
- Canadian Overseas Petroleum имеет Акции в свободном обращении из 259.371M 157.89%
- Lapco имеет Акции в свободном обращении из 259.400M 64.85%
- Organto Foods имеет Акции в свободном обращении из 259.421M 93.52%
- JiaChen имеет Акции в свободном обращении из 259.440M 25.94%